{"commentary":{"count":25,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":14,"podcast":9,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05555732\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05555732","nct_id":"NCT05555732","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05555732. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m\\^2 or carboplatin area under the curve \\[AUC) 5\\]).","label":"Dato-DXd + Pembrolizumab + Platinum Chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.","label":"Dato-DXd + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m\\^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m\\^2 or carboplatin area under the curve \\[AUC) 5\\]).","label":"Pembrolizumab + Pemetrexed + Platinum Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2031-05-11","type":"ESTIMATED"},"conditions":["Metastatic Non Small Cell Lung Cancer"],"enrollment":{"count":1170,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Datopotamab Deruxtecan","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-06-23","lead_sponsor":"Daiichi Sankyo","official_title":"A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-05-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 43 months"},{"measure":"Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positive","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 43 months"},{"measure":"Overall Survival in All Randomized Participants","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 76 months"},{"measure":"Overall Survival in All Randomized Participants who are TROP2 NMR positive","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 76 months"}],"references":[{"citation":"Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen A, Rajagopalan R, Lisberg AE. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab +/- platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024;20(37):2927-2936. doi: 10.1080/14796694.2024.2409621. Epub 2024 Oct 29.","pmid":"39469838","type":"DERIVED"}],"start_date":{"date":"2023-01-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","url":"https://clinicaltrials.gov/study/NCT05555732"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05555732"}